XBiotech

XBiotech R&D per Employee

The R&D Spending per Employee of XBiotech (XBIT) as of Oct 10, 2026 is 752,222.22 USD. In the previous year, R&D Spending per Employee was 599,317.46 USD — a change of 25.51% (higher).

R&D per Employee

752,222.22USD

YoY

25.51%

Last updated:

R&D Spending per Employee of XBiotech is 2025 752,222.22 USD. R&D Spending per Employee of XBiotech was 2024 599,317.46 USD. It decreases by 25.51% higher compared to the previous year.

The XBiotech R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
249,603.17 USD
Jan 1, 2019
382,380.95 USD
Jan 1, 2020
151,222.22 USD
Jan 1, 2021
448,698.41 USD
Jan 1, 2022
500,698.41 USD
Jan 1, 2023
521,396.83 USD
Jan 1, 2024
599,317.46 USD
Jan 1, 2025
752,222.22 USD
The XBiotech R&D per Employee history
YEARR&D per EmployeeYoY
752,222.22USD+25.51%
599,317.46USD+14.94%
521,396.83USD+4.13%
500,698.41USD+11.59%
448,698.41USD+196.71%
151,222.22USD-60.45%
382,380.95USD+53.20%
249,603.17USD-40.49%
419,428.57USD-37.81%
674,380.95USD+35.69%
496,984.13USD+118.51%
227,444.44USD—
Access this data via the Eulerpool API

XBiotech Stock analysis

What does XBiotech do? XBiotech Inc is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutics for immune system disorders. The company was founded in 2008 in Texas, USA, and focuses on the production of monoclonal antibodies for the treatment of inflammatory diseases. The company's focus is on oncology and autoimmune diseases. By developing drugs that strengthen the body's immune defenses, the goal is to enable the immune system to fight diseases. This particularly involves T-cell-based immunotherapies that can be used in the treatment of cancer, autoimmune diseases, and infectious diseases. XBiotech has had an impressive track record in recent years. The company has obtained several FDA approvals for its products and has expanded rapidly into other parts of the world, including Europe and Asia. XBiotech's innovative business model involves developing therapeutic products that have a targeted effect on specific bodily processes. Currently, the company produces several therapeutics, including Xilonix, True Human, and hXBP-1. These products are used in the treatment of various inflammatory diseases, including Crohn's disease, diabetes, and other autoimmune diseases. XBiotech emphasizes that its products are fully human antibodies, unlike traditional antibodies, which have higher effectiveness and lower risk of side effects. Xilonix is a medication used for the treatment of metastatic colorectal cancer. It works by activating the body's immune system to more effectively fight cancer cells. True Human is a monoclonal antibody used in the treatment of inflammatory diseases such as Crohn's disease and rheumatoid arthritis. And hXBP-1 is a therapeutic protein developed to assist in the treatment of diabetes and obesity. XBiotech has also conducted several controlled studies to demonstrate the effectiveness of its products. These studies have shown the positive impact of XBiotech's products on patient health and have helped establish the company as a leading player in the field of immunotherapy. XBiotech has the potential to revolutionize the healthcare industry in the coming years. With its focus on developing innovative immunotherapies and its currently successful products on the market, the company has the opportunity to change the way we treat diseases. Overall, XBiotech is a biopharmaceutical company specializing in the development of drugs for the treatment of inflammatory diseases. The company has had an impressive track record in recent years and has the potential to change the medical landscape. XBiotech produces products that strengthen the body's immune system while minimizing the risk of side effects. With a focus on innovative immunotherapies, XBiotech is well positioned to make significant progress in the treatment of cancer, autoimmune diseases, and infectious diseases. XBiotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about XBiotech stock

R&D Spending per Employee of XBiotech is 752,222.22 USD in 2025.

R&D Spending per Employee of XBiotech changed from 599,317.46 USD to 752,222.22 USD, representing a 25.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee XBiotech since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's XBiotech historically and in real time.

Access this data via the Eulerpool API

Workforce — XBiotech

All Key Metrics — XBiotech